Key result
Metformin and SGLT2i may lower AF risk in diabetes while insulin is linked to higher risk.
Why the study?
Despite extensive epidemiological evidence linking diabetes mellitus and atrial fibrillation, the underlying mechanisms and the influence of glucose-lowering therapies on AF susceptibility remain incompletely defined.
How do different glucose-lowering drugs impact the risk of atrial fibrillation in patients with diabetes mellitus?
How do different glucose-lowering drugs impact the risk of atrial fibrillation in patients with diabetes mellitus?
Glucose-lowering therapies have heterogeneous effects on atrial fibrillation risk in diabetic patients, with metformin and SGLT-2 inhibitors showing favorable or neutral profiles compared to the increased risk associated with insulin.
Answers are grounded in this paper and cite their sources.
Should not yet change prescribing in diabetes; leaves open confirmation of AF risk reduction with metformin or SGLT2 inhibitors versus insulin in prospective trials.
Background/Objectives: Diabetes mellitus (DM) represents a major global public health challenge and is consistently associated with an increased risk of atrial fibrillation (AF). Despite extensive epidemiological evidence linking the two conditions, the underlying mechanisms and the influence of glucose-lowering therapies on AF susceptibility remain incompletely defined. This review aims to summarize the current knowledge on the pathophysiological pathways linking DM and AF and to assess the impact of commonly used antidiabetic therapies on arrhythmic risk. We conducted a narrative review of epidemiological studies, mechanistic research, and cardiovascular outcome trials that evaluate the association between DM and AF. We included data addressing structural, electrical, autonomic, metabolic, and inflammatory mechanisms of AF in diabetes, as well as clinical evidence regarding the impact of metformin, insulin, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium–glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists on AF incidence or recurrence. Results: DM promotes AF development through multiple complementary mechanisms, including atrial fibrosis, electrical conduction abnormalities, autonomic dysfunction, inflammation, glycemic fluctuations, oxidative stress, and expansion of epicardial adipose tissue. These changes create a vulnerable atrial substrate that facilitates both initiation and maintenance of AF. Evidence from recent trials indicates that the arrhythmic effects of glucose-lowering therapies are heterogeneous. Metformin and SGLT-2 inhibitors appear to offer favorable or neutral effects on AF risk. GLP-1 receptor agonists provide substantial cardiovascular benefits, although their specific impact on AF remains under investigation. Insulin therapy has been linked to a higher AF risk, whereas DPP-4 inhibitors show an overall neutral effect with inconsistent findings across studies. Conclusions: AF in patients with DM results from complex interactions between metabolic disturbances, structural remodeling, and inflammatory activation. Although several antidiabetic drugs appear to have potential antiarrhythmic effects, further dedicated research is needed to clarify their role in AF prevention and management.
No takes yet. Share an insight, caveat, or question.
Grigore et al. (2025) studied this question. Metformin and SGLT-2 inhibitors may have favorable effects on atrial fibrillation risk in diabetes, while insulin therapy is associated with higher risk.
Synapse has enriched 10 related papers. Consider them for comparative context: